Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98770 | 0.94 | — | — | |
| SCHEMBL27705013 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL27437639 | 0.92 | — | — | |
| SCHEMBL28119764 | 0.92 | — | — | |
| Oxalic Acid SCHEMBL27581908 | 0.92 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1MAPTCA12 | |
| Hydrochloric Acid SCHEMBL943803 | 0.92 | — | — | |
| SCHEMBL28863989 | 0.92 | — | — | |
| Fluoride SCHEMBL27810482 | 0.92 | — | — | |
| SCHEMBL29240048 | 0.92 | — | — | |
| SCHEMBL28035895 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012486-B2 | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | CHUNG-ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2011-09-06 | — | — | US | disclosed |
| US-7939623-B2 | Composition containing flavan compound | TOYO SHINYAKU CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7863466-B2 | Method of producing proanthocyanidin-containing material | TOYO SHINYAKU CO., LTD. (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20100190729-A1 | Composition for treating atopic dermatitis comprising hirsutanonol or oregonin as an active ingredient | CHUNG-ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190862-A1 | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | CHUNG-ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20090124818-A1 | METHOD OF PRODUCING PROANTHOCYANIDIN-CONTAINING MATERIAL | TOYO SHINYAKU CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20070293415-A1 | Composition Containning Flavan Compound | TOYO SHINYAKU CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070184126-A1 | Water-soluble bound matter of proanthocyandin and composition containing the same | TOYO SHINYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060177525-A1 | Process for producing proanthocyanin-rich material | TOYO SHINYAKU CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1602653-A1 | PROCESS FOR PRODUCING PROANTHOCYANIN-RICH MATERIAL | Toyo Shinyaku Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20050158409-A1 | Food improving blood flow | TOYO SHINYAKU CO., LTD. (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1547591-A1 | FOOD IMPROVING BLOOD FLOW | Toyo Shinyaku Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190729-A1 | Composition for treating atopic dermatitis comprising hirsutanonol or oregonin as an active ingredient | MBTD1, DBNL, HMOX2 | MEN1 2989/4885KMT2A 4193/4885ALDH1A1 422/4885 |
| US-20100190862-A1 | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | IL5, IL4, IL17A | MEN1 4584/4885KMT2A 2112/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.